Pàgina inicial > Resultats de la cerca: Opat, S.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
12 p, 1.1 MB Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL : primary analysis of the CAPTIVATE FD cohort / Tam, Constantine S (University of Melbourne) ; Allan, John N (Weill Cornell Medicine) ; Siddiqi, Tanya (City of Hope National Medical Center) ; Kipps, Thomas J. (University of California San Diego) ; Jacobs, Ryan (Levine Cancer Institute) ; Opat, Stephen (Monash University) ; Barr, Paul M. (University of Rochester Medical Center) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Trentin, Livio (University of Padova) ; Bannerji, Rajat (Rutgers Cancer Institute of New Jersey) ; Jackson, Sharon (Middlemore Hospital) ; Kuss, Bryone J. (Flinders University and Medical Center) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Szafer-Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ; Russell, Kristin (Pharmacyclics LLC. an AbbVie Company) ; Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ; Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ; Wierda, William G. (DepaUniversity of Texas MD Anderson Cancer Center) ; Ghia, Paolo (IRCCS Ospedale San Raffaele) ; Universitat Autònoma de Barcelona
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. [...]
2022 - 10.1182/blood.2021014488
Blood, Vol. 139 Núm. 22 (february 2022) , p. 3278-3289  
Registre complet - Creative Commons
2.
15 p, 664.9 KB Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study / Wierda, W. G. (University of Texas.) ; Allan, J. N. (Weill Cornell Medicine) ; Siddiqi, Tanya (City of Hope National Medical Center) ; Kipps, T. J. (UCSD. Moores Cancer Center) ; Opat, S. (Monash University) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Badoux, X. C. (Ministry of Health) ; Kuss, B. J. (Flinders University. Medical Centre) ; Jackson, Sharon (Middlemore Hospital) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Jacobs, R. M. D. (Levine Cancer Institute) ; Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ; Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ; Pak, Y. (Pharmacyclics LLC. AbbVie Company) ; Zhou, Cathy (Pharmacyclics LLC. AbbVie Company) ; Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ; Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ; Dean, James P (Pharmacyclics LLC. AbbVie Company) ; James, D. F. (Pharmacyclics LLC. AbbVie Company) ; Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ; Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ; Universitat Autònoma de Barcelona
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). [...]
2021 - 10.1200/JCO.21.00807
Journal of Clinical Oncology, Vol. 39 Núm. 34 (january 2021) , p. 3853-3865  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
1 Opat, Stephen
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem